The mysterious case of Eli Lilly’s obesity drug
-
By
-
Elaine Chen
-
Allison DeAngelis
-
June 25, 2026
-
Clinical Scorecard: Unraveling the Enigma Surrounding Eli Lilly's Obesity Treatment
At a Glance
| Category | Detail |
|---|
| Condition | Obesity |
| Key Mechanisms | Retatrutide as a treatment candidate |
| Target Population | Individuals with obesity |
| Care Setting | FDA compassionate use program |
Key Highlights
- Eli Lilly's obesity candidate retatrutide granted access through compassionate use
- Discussion on mergers and acquisitions in the pharmaceutical industry
- Exploration of Lilly's interest in a hair loss drug
- FDA's reversal on rare disease drug approvals
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Not specified
Access granted to one individual through compassionate use
Clinical Best Practices
Related Resources & Content
